CyFlow™ CD34 APC
| Antibody: | Yes |
| Antigen: | CD34 |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | 4H11[APG] |
| Emission Maximum: | 660 nm |
| Excitation Maximum: | 650 nm |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | APC |
| Isotype: | IgG1 |
| Laser: | Red |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | BW373714 |
For Research Use Only
| HLDA Workshop | HLDA VI—WS Code M MA58 |
| Quantity | 100 tests |
| Volume | 1.0 mL |
| Immunogen | Permanent human cell line derived from peripheral leucocytes of a patient suffering from chronic myeloid leukaemia |
| Background Information | CD34 (Mucosialin) is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions. |
| Usage | The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests. |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor‑mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti‑HPCA‑1. J Hematother Stem Cell Res. 2001 Dec; 10(6):863‑71. < PMID: 11798512 > | Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003 Jan 1; 101(1):112‑8. < PMID: 12589631 > | Kish DD, Gorbachev AV, Fairchild RL: CD8+ T cells produce IL‑2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses. J Leukoc Biol. 2005 Sep; 78(3):725‑35. < PMID: 16000396 > | Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three‑dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk‑L. Stem Cells Dev. 2005 Oct; 14(5):470‑7. < PMID: 16305332 > | Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev. 2006 Jun; 15(3):305‑13. < PMID: 16846369 > | Elknerová K, Lacinová Z, Soucek J, Marinov I, Stöckbauer P: Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. Neoplasma. 2007; 54(4):311‑20. < PMID: 17822321 >